Shanghai Haohai Biological Tech Co (SHG:688366) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Haohai Biological Tech Co (688366)
Shanghai Haohai Biological Tech Co (SHG:688366) has a market capitalization of $839.16 Million (CN¥5.73 Billion) as of June 23, 2026. Listed on the SHG stock exchange, this China-based company holds position #9852 globally and #2622 in its home market, demonstrating a -4.59% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Haohai Biological Tech Co's stock price CN¥30.15 by its total outstanding shares 190203760 (190.20 Million). Review 688366 total debt and obligations to assess the company's total debt and financial obligations.
Shanghai Haohai Biological Tech Co Market Cap History: 2019 to 2026
Shanghai Haohai Biological Tech Co's market capitalization history from 2019 to 2026. Data shows change from $2.45 Billion to $839.16 Million (-19.57% CAGR).
Shanghai Haohai Biological Tech Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Haohai Biological Tech Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.63x
Shanghai Haohai Biological Tech Co's market cap is 0.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.01x
Shanghai Haohai Biological Tech Co's market cap is 4.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $2.45 Billion | $1.60 Billion | $370.78 Million | 1.54x | 6.61x |
| 2020 | $2.47 Billion | $1.32 Billion | $230.07 Million | 1.87x | 10.74x |
| 2021 | $3.46 Billion | $1.75 Billion | $352.23 Million | 1.98x | 9.82x |
| 2022 | $2.70 Billion | $2.10 Billion | $180.47 Million | 1.28x | 14.97x |
| 2023 | $3.01 Billion | $2.63 Billion | $416.12 Million | 1.14x | 7.24x |
| 2024 | $1.69 Billion | $2.68 Billion | $420.45 Million | 0.63x | 4.01x |
Competitor Companies of 688366 by Market Capitalization
Companies near Shanghai Haohai Biological Tech Co in the global market cap rankings as of June 23, 2026.
Key companies related to Shanghai Haohai Biological Tech Co by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Shanghai Haohai Biological Tech Co Historical Marketcap From 2019 to 2026
Between 2019 and today, Shanghai Haohai Biological Tech Co's market cap moved from $2.45 Billion to $ 839.16 Million, with a yearly change of -19.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥839.16 Million | -31.32% |
| 2025 | CN¥1.22 Billion | -27.53% |
| 2024 | CN¥1.69 Billion | -44.06% |
| 2023 | CN¥3.01 Billion | +11.53% |
| 2022 | CN¥2.70 Billion | -21.88% |
| 2021 | CN¥3.46 Billion | +39.96% |
| 2020 | CN¥2.47 Billion | +0.81% |
| 2019 | CN¥2.45 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Shanghai Haohai Biological Tech Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $839.16 Million USD |
| MoneyControl | $839.16 Million USD |
| MarketWatch | $839.16 Million USD |
| marketcap.company | $839.16 Million USD |
| Reuters | $839.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Haohai Biological Tech Co
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyal… Read more